Literature DB >> 19937362

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women.

Ramazan Sari1, Esin Eray, Sabahat Ozdem, Halide Akbas, Erkan Coban.   

Abstract

Sibutramine and metformin are drugs commonly used to obtain weight loss. We aimed to compare the effects of sibutramine alone with that of sibutramine plus metformin combination on weight loss, insulin sensitivity, leptin and C reactive protein in obese women. Seventy obese women were included. After a diet period of month (baseline), each individual was randomly assigned to receive 15 mg sibutramine (sibutramine group; n = 36) or 15 mg sibutramine plus 1,700 mg metformin per day (sibutramine plus metformin group; n = 34) during the next 12 months. Body weight, insulin resistance by the homeostasis model assessment model (HOMA-IR), leptin and C reactive protein were measured at baseline, after 3 months and after 12 months. Mean weight losses in sibutramine and sibutramine plus metformin groups were 5.3 +/- 4.0% (P < 0.001) and 6.8 +/- 3.9% (P < 0.001) after 3 months, and 10.5 +/- 4.4% (P < 0.001) and 15.7 +/- 4.6% (P = 0.007) after 12 months, respectively. HOMA-IR value also decreased in both sibutramine (P = 0.045 and P = 0.002) and sibutramine plus metformin groups (P = 0.04 and P = 0.015) after 3 and 12 months, respectively. Similarly, serum leptin levels decreased in both sibutramine (P = 0.04, P = 0.01) and sibutramine plus metformin groups (P = 0.023, P = 0.025) after 3 and 12 months, respectively. There was also significant reductions in serum C reactive protein levels in both sibutramine (P = 0.045, P = 0.02) and sibutramine plus metformin groups (P = 0.007, P = 0.001) after 3 and 12 months, respectively. These decrements of body weight, HOMA-IR, serum leptin and C reactive protein levels were not statistical significance between these two groups both after 3 and 12 months (P > 0.05). Combination of sibutramine with metformin did not result in any further effects on weight loss, insulin resistance, leptin and C reactive protein levels when compared to sibutramine alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937362     DOI: 10.1007/s10238-009-0080-y

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  34 in total

Review 1.  Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.

Authors: 
Journal:  Obes Res       Date:  1998-09

2.  Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.

Authors:  M Weintraub; P R Sundaresan; M Madan; B Schuster; A Balder; L Lasagna; C Cox
Journal:  Clin Pharmacol Ther       Date:  1992-05       Impact factor: 6.875

Review 3.  Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.

Authors:  C A Luque; J A Rey
Journal:  Ann Pharmacother       Date:  1999-09       Impact factor: 3.154

4.  Beneficial effects of metformin in normoglycemic morbidly obese adolescents.

Authors:  J P Kay; R Alemzadeh; G Langley; L D'Angelo; P Smith; S Holshouser
Journal:  Metabolism       Date:  2001-12       Impact factor: 8.694

5.  Insulin-leptin-visceral fat relation during weight loss.

Authors:  I Yip; V L Go; J M Hershman; H J Wang; R Elashoff; S DeShields; Y Liu; D Heber
Journal:  Pancreas       Date:  2001-08       Impact factor: 3.327

6.  Long-term drug treatment of obesity in a private practice setting.

Authors:  R L Atkinson; R C Blank; D Schumacher; N V Dhurandhar; D L Ritch
Journal:  Obes Res       Date:  1997-11

7.  Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.

Authors:  T A Wadden; R I Berkowitz; L G Womble; D B Sarwer; M E Arnold; C M Steinberg
Journal:  Obes Res       Date:  2000-09

8.  Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.

Authors:  A Gokcel; Y Gumurdulu; H Karakose; E Melek Ertorer; N Tanaci; N BascilTutuncu; N Guvener
Journal:  Diabetes Obes Metab       Date:  2002-01       Impact factor: 6.577

9.  Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.

Authors:  E M Velazquez; S Mendoza; T Hamer; F Sosa; C J Glueck
Journal:  Metabolism       Date:  1994-05       Impact factor: 8.694

Review 10.  Beneficial health effects of modest weight loss.

Authors:  D J Goldstein
Journal:  Int J Obes Relat Metab Disord       Date:  1992-06
View more
  2 in total

Review 1.  Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients.

Authors:  Konstantinos Tziomalos; Hariklia V Dimitroula; Niki Katsiki; Christos Savopoulos; Apostolos I Hatzitolios
Journal:  Mediators Inflamm       Date:  2010-03-07       Impact factor: 4.711

2.  Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat.

Authors:  Nelly Mauras; Charles DelGiorno; Jobayer Hossain; Keisha Bird; Kelleigh Killen; Debbie Merinbaum; Arthur Weltman; Ligeia Damaso; Prabhakaran Balagopal
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.